- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00093925
Clevidipine in the Postoperative Treatment of Hypertension (ECLIPSE-NIC) (ECLIPSE-NIC)
May 5, 2014 updated by: The Medicines Company
Evaluation of Clevidipine in the Postoperative Treatment of Hypertension Assessing Safety Events (With Nicardipine as Active Comparator) (ECLIPSE-NIC)
The purpose of this study is to establish the safety of clevidipine in the treatment of postoperative hypertension.
Approximately 250-500 patients with postoperative hypertension after undergoing coronary artery bypass grafting (CABG), off-pump coronary artery bypass (OPCAB) or minimally invasive direct coronary artery bypass (MIDCAB) surgery and/or valve replacement/repair procedures were anticipated to be randomly assigned to one of two treatment groups: clevidipine or nicardipine.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The primary objective was to establish the safety of clevidipine in the treatment of postoperative hypertension, as assessed by comparing the incidences of death, stroke, MI and renal dysfunction in the clevidipine and nicardipine treatment groups from the initiation of study drug infusion through postoperative Day 30.
Secondary objectives were to evaluate the efficacy of study drug, assessed by the blood pressure (BP) lowering effect, and additional safety variables.
Study Type
Interventional
Enrollment (Actual)
739
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alabama
-
Mobile, Alabama, United States, 36607
- Mobile Infirmary Medical Center
-
-
Kansas
-
Wichita, Kansas, United States, 67214
- Wesley Medical Center
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70121
- Ochsner Clinic Foundation
-
New Orleans, Louisiana, United States, 70115
- Touro Infirmary
-
-
New York
-
Bronx, New York, United States, 10467
- Montefiore Medical Center
-
Bronx, New York, United States, 10461
- Jack D. Weller Hospital
-
New York, New York, United States, 10032
- Columbia University - College of Physicians and Surgeons
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Hospital of the University of Pennsylvania
-
-
Virginia
-
Richmond, Virginia, United States, 23249
- VA Medical Center McGuire
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Prerandomization Inclusion Criteria:
- Provide written informed consent before initiation of any study related procedures.
- Be at least 18 years of age
- Be scheduled for Coronary Artery Bypass Grafting (CABG), Off Pump Coronary Artery Bypass (OPCAB), Minimally Invasive Direct Coronary Artery Bypass (MIDCAB) surgery, and/or valve replacement/repair surgery
Prerandomization Exclusion Criteria:
- Women of child-bearing potential (unless they have a negative pregnancy test)
- Recent cerebrovascular accident (within 3 months before randomization)
- Known intolerance to calcium channel blockers
- Known or suspected hypersensitivity to nicardipine
- Allergy to soybean oil or egg lecithin (components of the lipid vehicle)
- Pre-existing permanent ventricular pacing
- Any other disease or condition, which, in the judgment of the investigator would place a patient at undue risk by being enrolled in the trial
- Participation in another therapeutic drug or therapeutic device trial within 30 days of starting study
Postrandomization Inclusion Criteria:
- Expected to survive beyond 24 hours post-surgical procedure
- No surgical complications or conditions, present or anticipated, that preclude them from inclusion in the study
- Determined to be hypertensive postoperatively as determined by the investigator
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: clevidipine
Clevidipine (0.5 mg/mL in 20% lipid emulsion) was initiated after insertion of an arterial line upon the occurrence of postoperative hypertension, as determined by the investigator, and was administered intravenously (IV) at an initial infusion rate of 0.4 μg/kg/min (non weight-based equivalent is 2 mg/h).
Clevidipine was titrated to blood pressure lowering effect by doubling increments approximately every 90 seconds up to a maximum infusion rate of 3.2 μg/kg/min (16 mg/h).
Infusion rates above 3.2 μg/kg/min were permitted up to the maximum infusion rate of 8.0 μg/kg/min.
Treatment was maintained as long as was deemed clinically necessary or until discharge from the ICU.
Infusion rates between 4.4 and 8.0 μg/kg/min were to be administered for no more than 2 hours.
|
Other Names:
|
ACTIVE_COMPARATOR: nicardipine
Nicardipine (NIC) was initiated after insertion of an arterial line upon the occurrence of postoperative hypertension, as determined by the investigator, and was administered intravenously as per institutional practice.
Treatment was maintained as long as was deemed clinically necessary or until discharge from the ICU.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence of death, stroke, MI, and renal dysfunction
Time Frame: Initiation of study drug infusion through post-operative Day 30
|
Initiation of study drug infusion through post-operative Day 30
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2004
Primary Completion (ACTUAL)
July 1, 2006
Study Completion (ACTUAL)
September 1, 2006
Study Registration Dates
First Submitted
October 7, 2004
First Submitted That Met QC Criteria
October 7, 2004
First Posted (ESTIMATE)
October 8, 2004
Study Record Updates
Last Update Posted (ESTIMATE)
May 6, 2014
Last Update Submitted That Met QC Criteria
May 5, 2014
Last Verified
May 1, 2014
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- TMC-CLV-03-05
- ECLIPSE-NIC (OTHER: Sponsor)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
BayerCompletedPrimary HypertensionChina
-
Columbia UniversityAgency for Healthcare Research and Quality (AHRQ)Active, not recruitingWhite Coat Hypertension | Hypertension,EssentialUnited States
-
Addpharma Inc.Completed
-
Universidade Federal de Santa MariaCompletedHealthy Volunteers | Hypertension, EssentialBrazil
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom
-
China Academy of Chinese Medical SciencesGuang'anmen Hospital of China Academy of Chinese Medical SciencesCompletedHypertension, Resistant to Conventional Therapy | Primary HypertensionChina
-
Sulaiman AlRajhi CollegesUnknownHypertension, Essential | β-hydroxybutyrate
Clinical Trials on clevidipine
-
The Medicines CompanyCompleted
-
The Medicines CompanyCompletedHypertension | HemorrhageUnited States, Germany
-
The Medicines CompanyCompleted
-
Asma Zainab, M.D.The Medicines Company; The Methodist Hospital Research InstituteTerminatedAortic Aneurysm | Aortic DiseaseUnited States
-
The Medicines CompanyCompleted
-
Chiesi Farmaceutici S.p.A.WithdrawnPediatric Perioperative Blood Pressure ManagementUnited States
-
The Medicines CompanyCompletedHypertensionUnited States
-
The Medicines CompanyCompletedHypertensionUnited States
-
Henry Ford Health SystemUnknownSubarachnoid Hemorrhage | Vasospasm, Intracranial | Cerebral AneurysmUnited States
-
The Medicines CompanyCompletedHypertensionUnited States